logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table PPP-9. Composition of illicit drug tablets, 2011

Part (i) Content of synthetic scheduled illicit drugs

Country
Number of tabletsMDMA-like Substance {as the only scheduled substances}(Meth)Amphetamine {as the only scheduled substances}MDMA-like Substance and (Meth)Amphetamine {as the only scheduled substances}Other {scheduled substances}MiscellaneousTotal
Belgium(1)8240.010.80.07.741.5100
Bulgaria(1)17613.630.70.60.055.1100
Czech Republic19840.00.00.060.00.0100
Denmark3312.00.00.068.020.0100
Germany75487695.33.80.00.90.0100
Estonia(1)6799.40.480.00.00.1100
Ireland:::::::
Greece177920.80.00.00.079.2100
Spain12595.10.050.41.742.8100
France-A(1)31026.04.00.010.060.0100
France-B4562.217.88.90.011.1100
Italy2928.07.00.024.041.0100
Cyprus57240.114.60.045.30.0100
Latvia(1)23612.00.010.010.088.0100
Lithuania:::::::
Luxembourg1533.346.70.020.00.0100
Hungary(1)4714.31.10.00.094.7100
Malta2100100.00.00.00.00.0100
Netherlands224287.02.03.01.07.0100
Austria14549.70.70.011.737.9100
Poland(1)1741.024.00.030.05.0100
Portugal14275.00.00.70.024.3100
Romania:::::::
Slovenia1870.010.00.010.010.0100
Slovakia13420.29.00.035.835.1100
Finland13081.56.92.36.23.1100
Sweden196000.60.00.50.098.9100
United Kingdom(1)425543.0<10.0<156.0100
Croatia(1)4250.04.82.411.831.0100
Turkey729320.066.02.01.011.0100
Norway2250024.032.00.04.040.0100
 

Notes:

The table seeks to monitor synthetic scheduled illicit drugs - i.e. drugs controlled under the 1971 UN Convention on Psychotropic Substances Schedules I and II and under European legislation (Council Decisions), providing data on the contents of illicit drug tablets from different sources (seizures, users' submissions, etc.).

(1) This figure 'Number of tablets' refers to the total number of records analysed; that is the number of different tablet types analysed.

For methodological information: source, sampling frame and type of study, please refer to Table PPP-9 part(ii). and Table PPP-9 part(iii).

For additional available information on substances included in categories 'Miscellaneous' and 'Other', please refer to Table PPP-9 part(iv).

Source:

Reitox national focal points.

Page last updated: Friday, 26 April 2013